Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rabies vaccine inactivated - Sanofi

Drug Profile

Rabies vaccine inactivated - Sanofi

Alternative Names: Purified Vero Rabies Vaccine - Sanofi; Purified vero rabies vaccine - serum free; Rabies VRVg; SP-0087; Vero cell human rabies vaccine; VerorabVax; VRVg 1; VRVg 2

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 17 Oct 2022 Registered for Rabies (In adolescents, In children, In infants, Prevention, In adults) in Australia (IM)
  • 21 Aug 2022 Sanofi completes a phase-III clinical trial in Rabies (Prevention, In children, In adolescents, In adults, In the elderly, In infants) in Thailand (Intradermal) (NCT04478084)
  • 22 Aug 2021 Sanofi completes a phase III trial for Rabies (Prevention) in Thailand (IM) (NCT04127786) (EudraCT2019-000973-22)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top